Agitation and Aggression in Alzheimer's Disease
Neurology
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Acadia PharmaceuticalsSAN DIEGO, CA
2 programs2
PimavanserinPhase 21 trial
Pimavanserin 34 mgPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Acadia PharmaceuticalsPimavanserin
Acadia PharmaceuticalsPimavanserin 34 mg
Clinical Trials (2)
Total enrollment: 190 patients across 2 trials
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Start: Feb 2017Est. completion: Feb 201979 patients
Phase 2Completed
Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)
Start: Nov 2016Est. completion: Feb 2018111 patients
Phase 2Terminated
Related Jobs in Neurology
Director, Distribution & Services
Xenon Pharmaceuticals
Remote
10h ago
Senior Medical Science Liaison (NYC Tri-State)
Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr
Director of Medical Affairs
CoMind
Miami, FL
10h ago
Director of Finance
CoMind
London, UK
10h ago
Electronics Engineering Manager
CoMind
London, UK
10h ago
Director of Information Technology
Zavation Medical Products
10h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space